Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Section 5 of 6

Economic information and modeling report

15 evidence topics · 15 sources

Modeling overview

Summary

No source in this report presents a cost-effectiveness or budget impact model of COMP360 itself, and none quotes a price for it. ICER is assessing synthetic psilocybin against esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation, with a model analysis plan due January 22, 2027, a five-year health care system cost-effectiveness model, and a separate five-year budget impact analysis; its final evidence report is scheduled for 06/21/2027. Published analyses of psilocybin therapy report $117,517 per QALY gained over 12 months from a limited healthcare perspective, cost savings of approximately $7000 per patient compared with standard of care, and cost-effectiveness when the cost of therapist support was reduced by 50% and the psilocybin price to £400 to £800 per person. For the comparator, ICER's 2019 report estimated approximately $198,000 per QALY gained for esketamine. The company plans drug reimbursement through the pharmacy benefit and monitoring through CPT Category III codes, and presented health economics posters on real-world costs across TRD health states at Psych Congress 2026. A payer panel noted that the effect of psilocybin on later treatment needs leaves “an uncertain impact to the total cost of care.”

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.